| metastatic carcinoma | Q6823250 |
| prostate carcinoma | Q18553829 |
| Q58407616 | Docetaxel Followed by Provenge in Metastatic Prostate Cancer |
| Q58849551 | Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer |
| Q58848980 | Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy |
| Q89148644 | 68Ga-PSMA-HBED-CC-Avid Synchronous Urinary Bladder Paraganglioma in a Patient With Metastatic Prostate Carcinoma |
| Q73020024 | A 63-year-old otherwise healthy patient with bone metastatic prostate carcinoma of one year duration, with osteolytic metastasis to the left os pubis, os ischii and acetabulum |
| Q63581121 | A Phase 1 Clinical Trial of ARV-110 in Patients With Metastatic Castration-resistant Prostate Cancer. |
| Q66080384 | A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 |
| Q66034152 | A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer |
| Q64665661 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer |
| Q66032915 | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer |
| Q66037218 | A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer |
| Q65387121 | A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) |
| Q65359881 | A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease |
| Q64639455 | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) |
| Q65367921 | A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer |
| Q74280392 | A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
| Q64222983 | A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Can |
| Q65536362 | A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy |
| Q33374129 | A pilot trial of chemohormonal therapy for metastatic prostate carcinoma |
| Q74245175 | A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma |
| Q64650987 | Abiraterone Acetate Trial in African American Prostate Cancer Patients |
| Q64397427 | Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. |
| Q64354956 | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer |
| Q29617512 | Abiraterone and increased survival in metastatic prostate cancer |
| Q83992096 | Anti-laminin-332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: hypothesis for a paraneoplastic phenomenon |
| Q80056731 | Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes |
| Q92990015 | Automated Definition of Skeletal Disease Burden in Metastatic Prostate Carcinoma: A 3D Analysis of SPECT/CT Images |
| Q66388716 | BRcA Deficient Prostate Cancer Treated With Carboplatin or Docetaxel |
| Q72558446 | Bilateral ethmoid sinusitis with unilateral proptosis as an initial manifestation of metastatic prostate carcinoma |
| Q64170814 | Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer |
| Q44973326 | Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2004. A 63-year-old man with metastatic prostate carcinoma refractory to hormone therapy |
| Q37633767 | Chylothorax due to metastatic prostate carcinoma: an unusual complication |
| Q47367486 | Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients |
| Q73935811 | Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma |
| Q80828802 | Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes |
| Q53489177 | Detecting metastatic prostate carcinoma in pelvic lymph nodes following neoadjuvant hormone therapy: the eyes have it! |
| Q66029296 | Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer |
| Q65360009 | Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer |
| Q89507223 | Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) |
| Q64395963 | Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer |
| Q36829335 | Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule |
| Q66028522 | Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate |
| Q64631572 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer |
| Q83585819 | Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma |
| Q38456204 | Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. |
| Q89623418 | Feasibility Study and Preliminary Results of Prognostic Value of Bone SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma to Abiraterone |
| Q63818399 | Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients |
| Q63339123 | Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer |
| Q80805637 | Fine needle aspiration biopsy diagnosis of metastatic prostate carcinoma to inguinal lymph node |
| Q37582844 | Fine needle aspiration of metastatic prostate carcinoma simulating a primary adrenal cortical neoplasm: a case report and review of the literature |
| Q73978031 | Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma |
| Q71743152 | Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma |
| Q89435621 | Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers |
| Q64677092 | Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer |
| Q34674540 | High dose ketoconazole for the treatment of hormone refractory metastatic prostate carcinoma: 16 cases and review of the literature. |
| Q77056261 | Hormone therapy of locally advanced and metastatic prostate carcinoma |
| Q33940430 | Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells |
| Q66062805 | Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer |
| Q78136439 | Immunoreactivity of prostate-specific antigen in male breast carcinomas: two examples of a diagnostic pitfall in discriminating a primary breast cancer from metastatic prostate carcinoma |
| Q64186960 | Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer |
| Q44442306 | Influence of DNA ploidy and grading on survival in primary metastatic prostate carcinoma |
| Q40431138 | Internal jugular venous thrombosis due to Trousseau's syndrome as the presenting feature of metastatic prostate carcinoma: a case report |
| Q45047220 | Intracranial metastatic prostate carcinoma presenting as intermittent double vision |
| Q65358038 | Local Treatment With RP for Newly-diagnosed mPCa |
| Q50443309 | Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT. |
| Q57094151 | Metastatic Prostate Carcinoma from Imperial Rome (1st to 2nd Centuries AD) |
| Q70700519 | Metastatic prostate carcinoma manifesting as penile nodules |
| Q69779060 | Metastatic prostate carcinoma mimicking Paget's disease on bone imaging |
| Q36425441 | Metastatic prostate carcinoma mimicking meningioma: case report and review of the literature |
| Q82529299 | Metastatic prostate carcinoma mimicking primary anal cancer |
| Q80809725 | Metastatic prostate carcinoma presenting as numb chin syndrome in elderly people |
| Q39772653 | Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual? |
| Q44124134 | Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival |
| Q77379228 | Metastatic prostate carcinoma to the foot with magnetic resonance imaging and pathologic correlation |
| Q30919858 | Metastatic prostate carcinoma to the intradural extramedullary spinal compartment. Case report. |
| Q40474549 | Metastatic prostate carcinoma to the mandible: report of case |
| Q52874546 | Metastatic prostate carcinoma to the orbit as the first presentation of disease. |
| Q98465826 | Metastatic prostate carcinoma: A rare presentation initially misdiagnosed as a rib fracture |
| Q65538996 | Metronomic Oral Vinorelbine in Patients With Metastatic Tumors |
| Q67128851 | Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) |
| Q65347002 | Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients |
| Q72088614 | Oncogenic osteomalacia associated with metastatic prostate carcinoma |
| Q40863943 | Oncogenic osteomalacia associated with metastatic prostate carcinoma: case report and review of the literature |
| Q81098696 | Oral and maxillofacial pathology case of the month. Metastatic prostate carcinoma (osteoblastic metastasis) |
| Q64348851 | PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer |
| Q86257887 | PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn |
| Q95172103 | PROState Pathway Embedded Comparative Trial |
| Q33340910 | PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma |
| Q64649606 | Pazopanib, Docetaxel, Prednisone Prostate |
| Q66047068 | Phase I Trial of PACE for Metastatic Prostate Cancer |
| Q64719361 | Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) |
| Q72262465 | Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group |
| Q82056996 | Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma |
| Q83242602 | Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? |
| Q67134648 | Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer |
| Q64673147 | Prostate Cancer Prospective Cohort |
| Q71079510 | Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma |
| Q66390899 | Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer |
| Q81585612 | Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma |
| Q69881446 | Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma |
| Q48290410 | Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system |
| Q73014452 | Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma |
| Q67678281 | Response to orchiectomy following zoladentherapy for metastatic prostate carcinoma |
| Q64645319 | Second-line Chemotherapy in Castration Resistant Prostate Cancer |
| Q71018110 | Sensitivity of frozen section examination of pelvic lymph nodes for metastatic prostate carcinoma |
| Q63012565 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer |
| Q33330265 | Severe hemorrhage, lymphocytosis and leukoerythroblastic blood picture--disseminated intravascular coagulation in metastatic prostate carcinoma and chronic lymphatic leukemia |
| Q86153525 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (2016-11-30) |
| Q64139612 | Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer |
| Q86303755 | Study of Abiraterone Acetate, Atezolizumab, Lupron, and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer |
| Q63404222 | Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy |
| Q71410482 | Subcapsular orchiectomy with intracapsular testicular prosthesis for metastatic prostate carcinoma |
| Q73404520 | Tc-99m sestamibi uptake in metastatic prostate carcinoma |
| Q90942391 | The Great Mimicker-Tuberculosis Involving Prostate and Vertebrae Posing as Metastatic Prostate Carcinoma on FDG PET/CT |
| Q42588397 | Thoracic cord compression from metastatic prostate carcinoma with Lhermitte's "sign". |
| Q79112145 | Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC |
| Q39483987 | Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. |
| Q70053750 | Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex |
| Q42835604 | Unusual presentations of metastatic prostate carcinoma as detected by anti-3 F-18 FACBC PET/CT. |
| Q38446601 | Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. |
| Q61865309 | Vaccine and Antibody Treatment of Prostate Cancer |
| Q38469778 | Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors |
| Q52984721 | Widespread Metastatic Prostate Carcinoma Shown by 68Ga-PSMA PET/CT. |
| Q86587994 | [Acute complete left-side ophthalmoplegia as an initial manifestation of metastatic prostate carcinoma: a case report] |
| Q81217653 | [Hormone-refractory metastatic prostate carcinoma -- combination improves survival] |
| Q80716477 | [Identification of the molecular bases of metastasis for the development of new therapy strategies of metastatic prostate carcinoma] |
| Q82639097 | [Mental neuropathy and pathologic fracture of the mandible as initial symptoms of metastatic prostate carcinoma] |
| Q80229134 | [Metastatic prostate carcinoma mimicking a parotid tumor: a case report] |
| Q18975290 | metastatic prostatic adenocarcinoma | subclass of | P279 |
Search more.